跳至主要内容
临床试验/ISRCTN16270209
ISRCTN16270209已完成未知

A randomised controlled trial of a conversational virtual avatar-led cognitive behavioural therapy app intervention for improving the quality of life and mental health of people with epilepsy

Healios Ltd0 个研究点目标入组 255 人开始时间: 2022年3月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
Healios Ltd
入组人数
255

研究概览

简要总结

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36409536/ (added 22/11/2022)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 16/05/2022:
  • 1. Adult aged 18-65 years
  • 2. UK resident
  • 3. Fluent in English
  • 4. Scoring =5 on the GAD-7 indicating at least mild anxiety at screen-in (incl. diagnosed/non-diagnosed)
  • 5. The participant is willing and able to receive notifications and email messages
  • 6. Have a confirmed Epilepsy diagnosis (6 months minimum time since diagnosis, suspected cases are not permitted). Diagnosis to be confirmed ideally by participant submitting a photograph of their current medication and/or letter/report from their healthcare provider
  • 7. Stable epilepsy and anxiety/depression medication regime (anti-epileptic, antidepressant, anxiolytic drug etc. A stable medication regimen for the present study refers to no change in medication in the last 4 weeks. Questions to cover this at all data collection time points. Should participants change medication during the study period, this will not affect their inclusion, however, this will be explored in the analysis.
  • Previous inclusion criteria:
  • 1. Adult aged 18-65 years
  • 2. UK resident
  • 3. Fluent in English
  • 4. Clinical levels of anxiety (=10 on the GAD-7) at screen-in (incl. diagnosed/non-diagnosed)
  • 5. The participant is willing and able to receive notifications and email messages
  • 6. Have a confirmed Epilepsy diagnosis (6 months minimum time since diagnosis, suspected cases are not permitted). Diagnosis to be confirmed ideally by participant submitting a photograph of their current medication and/or letter/report from their healthcare provider
  • 7. Stable epilepsy and anxiety/depression medication regime (anti-epileptic, antidepressant, anxiolytic drug etc. A stable medication regimen for the present study refers to no change in medication in the last 4 weeks. Questions to cover this at all data collection time points. Should participants change medication during the study period, this will not affect their inclusion, however, this will be explored in the analysis.

排除标准

  • 1. Have a subclinical score on the GAD-7 at screening
  • 2. Have a score =20 on the PHQ-9 indicating severe depression at screen in or if they answer ‘more than half of the days’ or ‘nearly every day’’ to the question ‘Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?’
  • 3. Sensitivity to mobile phone screen exposure
  • 4. Currently receiving counselling or psychological therapy (however, will not be excluded if they seek support during the study)
  • 5. Individuals involved in current or ongoing research
  • 6. Pregnant or has given birth in the past 12 months
  • 7. Diagnosis of a severe mental illness (severe depression including suicidal ideation, schizophrenia, bipolar, psychosis, personality disorder, PTSD, substance misuse)
  • 8. Severe learning disability and individuals requiring a carer for their epilepsy
  • 9. Does not have access to a smartphone (iPhone with iOS 9 or greater capabilities, or an Android with OS 7 or greater capabilities)

研究者

发起方
Healios Ltd

相似试验

ThinkNinja for epilepsy: a cognitive behavioural... | 临床试验